Bone health in pediatric rheumatic disease

Kelly A. Rouster-Stevens, Marisa S Klein-Gitelman*

*Corresponding author for this work

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Purpose of review: Children with chronic rheumatic disease have decreased bone mass. In adults, lowered bone mineral density is associated with increased fracture risk. This morbidity is undetermined in pediatric rheumatic disease as osteoporosis has not been well-defined in children. This review compares methods for determining bone mass in children, examines insights into molecular mechanisms of bone metabolism, and discusses the prevention and treatment of decreased bone mass in children. Recent findings: Peak bone mass, attained during adolescence and early adulthood, is critical in determining fracture risk. Studies of children with chronic rheumatic disease demonstrate decreased bone mineral density, and potentially lowered peak bone mass. Dual energy x-ray absorptiometry is the most commonly used technique for monitoring bone mineral density and should be interpreted utilizing age-appropriate Z-scores. Recent studies suggest quantitative ultrasound may be as reliable as dual energy x-ray absorptiometry and lacks radiation exposure. The molecular mechanisms by which inflammation alters bone mineral density involve receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin, tumor necrosis factor-α, and interleukin-1. Limited data on the use of bisnphosphonates and calcitonin in children suggest they are safe and effective, but should be used cautiously. Summary: Children with chronic rheumatic disease should have bone mass monitored by dual energy x-ray absorptiometry Z-scores. Targeting the RANKL/osteoprotegerin pathway may lead to therapies that improve bone health in this population. More studies on the role of bisphosphonates and calcitonin must be pursued to establish guidelines for use in pediatric patients with chronic rheumatic disease. For now, supplemental calcium and vitamin D should be implemented in these children.

Original languageEnglish (US)
Pages (from-to)703-708
Number of pages6
JournalCurrent Opinion in Pediatrics
Volume17
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Rheumatic Diseases
Pediatrics
Bone and Bones
Health
Bone Density
Chronic Disease
X-Rays
Calcitonin
RANK Ligand
Osteoprotegerin
Diphosphonates
Cytoplasmic and Nuclear Receptors
Interleukin-1
Vitamin D
Osteoporosis
Tumor Necrosis Factor-alpha
Guidelines
Inflammation
Calcium
Morbidity

Keywords

  • Bone density
  • Dual energy x-ray absorptiometry
  • OPG (osteoprotegerin)
  • Pediatric rheumatic disease
  • RANKL

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Rouster-Stevens, Kelly A. ; Klein-Gitelman, Marisa S. / Bone health in pediatric rheumatic disease. In: Current Opinion in Pediatrics. 2005 ; Vol. 17, No. 6. pp. 703-708.
@article{625ea10dcf8c4f7a90b362f58a9d6353,
title = "Bone health in pediatric rheumatic disease",
abstract = "Purpose of review: Children with chronic rheumatic disease have decreased bone mass. In adults, lowered bone mineral density is associated with increased fracture risk. This morbidity is undetermined in pediatric rheumatic disease as osteoporosis has not been well-defined in children. This review compares methods for determining bone mass in children, examines insights into molecular mechanisms of bone metabolism, and discusses the prevention and treatment of decreased bone mass in children. Recent findings: Peak bone mass, attained during adolescence and early adulthood, is critical in determining fracture risk. Studies of children with chronic rheumatic disease demonstrate decreased bone mineral density, and potentially lowered peak bone mass. Dual energy x-ray absorptiometry is the most commonly used technique for monitoring bone mineral density and should be interpreted utilizing age-appropriate Z-scores. Recent studies suggest quantitative ultrasound may be as reliable as dual energy x-ray absorptiometry and lacks radiation exposure. The molecular mechanisms by which inflammation alters bone mineral density involve receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin, tumor necrosis factor-α, and interleukin-1. Limited data on the use of bisnphosphonates and calcitonin in children suggest they are safe and effective, but should be used cautiously. Summary: Children with chronic rheumatic disease should have bone mass monitored by dual energy x-ray absorptiometry Z-scores. Targeting the RANKL/osteoprotegerin pathway may lead to therapies that improve bone health in this population. More studies on the role of bisphosphonates and calcitonin must be pursued to establish guidelines for use in pediatric patients with chronic rheumatic disease. For now, supplemental calcium and vitamin D should be implemented in these children.",
keywords = "Bone density, Dual energy x-ray absorptiometry, OPG (osteoprotegerin), Pediatric rheumatic disease, RANKL",
author = "Rouster-Stevens, {Kelly A.} and Klein-Gitelman, {Marisa S}",
year = "2005",
month = "12",
day = "1",
doi = "10.1097/01.mop.0000184048.13263.88",
language = "English (US)",
volume = "17",
pages = "703--708",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Bone health in pediatric rheumatic disease. / Rouster-Stevens, Kelly A.; Klein-Gitelman, Marisa S.

In: Current Opinion in Pediatrics, Vol. 17, No. 6, 01.12.2005, p. 703-708.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bone health in pediatric rheumatic disease

AU - Rouster-Stevens, Kelly A.

AU - Klein-Gitelman, Marisa S

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose of review: Children with chronic rheumatic disease have decreased bone mass. In adults, lowered bone mineral density is associated with increased fracture risk. This morbidity is undetermined in pediatric rheumatic disease as osteoporosis has not been well-defined in children. This review compares methods for determining bone mass in children, examines insights into molecular mechanisms of bone metabolism, and discusses the prevention and treatment of decreased bone mass in children. Recent findings: Peak bone mass, attained during adolescence and early adulthood, is critical in determining fracture risk. Studies of children with chronic rheumatic disease demonstrate decreased bone mineral density, and potentially lowered peak bone mass. Dual energy x-ray absorptiometry is the most commonly used technique for monitoring bone mineral density and should be interpreted utilizing age-appropriate Z-scores. Recent studies suggest quantitative ultrasound may be as reliable as dual energy x-ray absorptiometry and lacks radiation exposure. The molecular mechanisms by which inflammation alters bone mineral density involve receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin, tumor necrosis factor-α, and interleukin-1. Limited data on the use of bisnphosphonates and calcitonin in children suggest they are safe and effective, but should be used cautiously. Summary: Children with chronic rheumatic disease should have bone mass monitored by dual energy x-ray absorptiometry Z-scores. Targeting the RANKL/osteoprotegerin pathway may lead to therapies that improve bone health in this population. More studies on the role of bisphosphonates and calcitonin must be pursued to establish guidelines for use in pediatric patients with chronic rheumatic disease. For now, supplemental calcium and vitamin D should be implemented in these children.

AB - Purpose of review: Children with chronic rheumatic disease have decreased bone mass. In adults, lowered bone mineral density is associated with increased fracture risk. This morbidity is undetermined in pediatric rheumatic disease as osteoporosis has not been well-defined in children. This review compares methods for determining bone mass in children, examines insights into molecular mechanisms of bone metabolism, and discusses the prevention and treatment of decreased bone mass in children. Recent findings: Peak bone mass, attained during adolescence and early adulthood, is critical in determining fracture risk. Studies of children with chronic rheumatic disease demonstrate decreased bone mineral density, and potentially lowered peak bone mass. Dual energy x-ray absorptiometry is the most commonly used technique for monitoring bone mineral density and should be interpreted utilizing age-appropriate Z-scores. Recent studies suggest quantitative ultrasound may be as reliable as dual energy x-ray absorptiometry and lacks radiation exposure. The molecular mechanisms by which inflammation alters bone mineral density involve receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin, tumor necrosis factor-α, and interleukin-1. Limited data on the use of bisnphosphonates and calcitonin in children suggest they are safe and effective, but should be used cautiously. Summary: Children with chronic rheumatic disease should have bone mass monitored by dual energy x-ray absorptiometry Z-scores. Targeting the RANKL/osteoprotegerin pathway may lead to therapies that improve bone health in this population. More studies on the role of bisphosphonates and calcitonin must be pursued to establish guidelines for use in pediatric patients with chronic rheumatic disease. For now, supplemental calcium and vitamin D should be implemented in these children.

KW - Bone density

KW - Dual energy x-ray absorptiometry

KW - OPG (osteoprotegerin)

KW - Pediatric rheumatic disease

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=28044470245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044470245&partnerID=8YFLogxK

U2 - 10.1097/01.mop.0000184048.13263.88

DO - 10.1097/01.mop.0000184048.13263.88

M3 - Review article

VL - 17

SP - 703

EP - 708

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 6

ER -